HK Stock Market Move | ASCLETIS-B(01672) is now up more than 6%. ASC30 has completed dosing the first batch of subjects, with experimental data expected to be obtained in the fourth quarter.

ASCLETIS-B (01672) is now up more than 6%, rising 6.18% to 9.28 Hong Kong dollars, with a trading volume of 11.8666 million Hong Kong dollars as of the time of writing. In terms of news, Ge Li Pharmaceutical announced that the Phase IIa study of ASC30, a small molecule oral GLP-1 receptor (GLP-1R) agonist for the treatment of obesity in the United States (NCT07002905), has completed dosing for the first group of subjects. The subjects are obese individuals or overweight individuals with at least one weight-related comorbidity. The company expects to receive top-line data from the 13-week Phase IIa study of ASC30 oral in the fourth quarter of this year. China Securities Co., Ltd. previously stated that Ge Li Pharmaceutical's ASC30 and ASC47 drugs made appearances at the ADA conference, and the future prospects of the products are worth noting. The SAD study of ASC30 showed that it has good pharmacokinetic characteristics and a long half-life, with good drug efficacy and safety, mainly with mild to moderate side effects. The study results for ASC47 showed that it has fat reduction, muscle gain, and weight loss effects in preclinical animal models, with promising results expected in human trials. In conclusion, we believe that the company's innovative pipeline is progressing with positive clinical results, indicating good drug efficacy and safety. We look forward to the future clinical results and are optimistic about the company's future development.